Sana Biotechnology SANA Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sana Biotechnology's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sana Biotechnology's stock-based comp?
- Sana Biotechnology (SANA) reported stock-based comp of $5.66M in Q1 2026.
- How has Sana Biotechnology's stock-based comp changed year-over-year?
- Sana Biotechnology's stock-based comp decreased by 19.4% year-over-year, from $7.02M to $5.66M.
- What is the long-term trend for Sana Biotechnology's stock-based comp?
- Over 4 years (2021 to 2025), Sana Biotechnology's stock-based comp has grown at a 3.3% compound annual growth rate (CAGR), from $22.36M to $25.46M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.